Back to search

Article

Long-term decreased cannabinoid type-1 receptor activity restores specific neurological phenotypes in the Ts65Dn mouse model of Down syndrome

2021-11-22

Abstract excerpt

Intellectual disability is the most prevalent and limiting hallmark of Down syndrome (DS), without any pharmacological treatment available. Neurodegeneration and neuroinflammation are relevant neurological features of DS reaching to early development of Alzheimer’s disease. Preclinical evidence suggests that the endocannabinoid system, an important neuromodulator on cognition and neuroinflammation, could act as be...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
e23b25f2-f096-5516-b890-6008d02ace4f
DOI
10.1101/2021.11.22.469296
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Long-term decreased cannabinoid type-1 receptor activity restores specific neurological phenotypes in the Ts65Dn mouse model of Down syndromeDOI 10.1101/2021.11.22.469296
Cognitive and pharmacological insights from the Ts65Dn mouse model of Down syndromeSemantic proximity
Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer.Semantic proximity
Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerationsSemantic proximity
Cannabinoid signaling modulation through JZL184 restores key phenotypes of a mouse model for Williams-Beuren syndromeSemantic proximity
CA1 pyramidal neuron gene expression mosaics in the Ts65Dn murine model of Down syndrome and Alzheimer's disease following maternal choline supplementationSemantic proximity
Overexpression of Dyrk1A Is Implicated in Several Cognitive, Electrophysiological and Neuromorphological Alterations Found in a Mouse Model of Down SyndromeSemantic proximity
Adult-onset fluoxetine treatment does not improve behavioral impairments and may have adverse effects on the Ts65Dn mouse model of Down syndrome.Semantic proximity
Epigallocatechin‐3‐gallate, a DYRK1A inhibitor, rescues cognitive deficits in <scp>D</scp>own syndrome mouse models and in humansSemantic proximity
The CB1 receptor interacts with cereblon and drives cereblon deficiency-associated memory shortfalls.Semantic proximity
Novel DYRK1A Inhibitor Rescues Learning and Memory Deficits in a Mouse Model of Down SyndromeSemantic proximity
The CB <sub>1</sub> receptor interacts with cereblon and drives cereblon deficiency-associated memory shortfallsSemantic proximity
Cannabinoid signaling modulation through JZL184 restores key phenotypes of a mouse model for Williams-Beuren syndrome.Semantic proximity
Select a neighboring publication to make it the new centre.